In experimental colitis, MCHR1 antagonist reduced colonic inflammation, probably by blocking IL10 upregulation, suggesting that inhibition of MCH/MCHR1 signaling could be a novel anti-inflammatory therapeutic approach (60, 61). The gene discussed is IL10; the disease is colitis.